Latest news with #Abatacept
Economic Times
11 hours ago
- Business
- Economic Times
Buy, Sell or Hold: Antique maintains Hold on Infosys; Nuvama maintains Buy on Dr Reddy's Laboratories
Live Events Antique on Infosys: Hold | Target price: Rs 1,750 Nuvama on Dr. Reddy's Laboratories: Buy | Target: Rs 1,486 | LTP: Rs 1,247 | Upside: 19% Motilal Oswal on Tata Consumer Products: Buy | Target: Rs 1,270 (earlier Rs 1,300) | LTP: Rs 1,062 | Upside: 19% (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Brokerages have shared their latest views on key Indian stocks, highlighting a mix of steady performance, emerging growth drivers, and sector-specific Antique has maintained a cautious stance on Infosys , citing margin pressures and limited changes in organic growth guidance, Nuvama remains optimistic about Dr. Reddy's Laboratories, driven by pipeline progress and a strong outlook for its CDMO Motilal Oswal has reiterated its bullish view on Tata Consumer Products , expecting margin expansion and synergies from recent acquisitions to support earnings a summary of their recommendations and insights for the next 12 have compiled key brokerage recommendations from ET Now and other sources:Antique has maintained a 'Hold' rating on Infosys with a target price of Rs 1,750. While the company delivered a strong quarterly performance, its organic growth guidance remains largely reported a robust total contract value (TCV) of $3.8 billion, reflecting solid deal bookings. However, discretionary spending remains weak, and the company continues to face margin headwinds. As a result, EPS estimates for FY26 and FY27 remain has maintained a 'Buy' rating on Dr. Reddy's Laboratories with a target price of Rs 1,486, implying a 19% upside from the last traded price of Rs 1, the company's Q1 performance was below expectations, new growth drivers are emerging. Semaglutide's progress in Canada remains on track, and a US filing for Abatacept is expected—both positive CDMO business is expected to contribute $100 million in FY26, with a target of reaching $300 million by FY30—a significant upside the company has reaffirmed its 25% margin guidance, backed by ongoing cost optimisation Oswal has reiterated its 'Buy' rating on Tata Consumer Products, revising the target price slightly to Rs 1,270 from Rs 1,300, indicating a 19% upside from the current price of Rs 1, brokerage expects moderating tea prices to support margin expansion starting Q2FY26. Consolidated margins are likely to improve, led by the tea business, while the international segment is expected to sustain its from the integration of Capital Foods and Organic India are also expected to boost the domestic food segment. The company has guided for ~16% EBITDA margin by has accordingly raised its EBITDA estimates for FY26 and FY27 by 7% and 3%, respectively.
Time of India
12 hours ago
- Business
- Time of India
Buy, Sell or Hold: Antique maintains Hold on Infosys; Nuvama maintains Buy on Dr Reddy's Laboratories
Brokerages have shared their latest views on key Indian stocks, highlighting a mix of steady performance, emerging growth drivers, and sector-specific tailwinds. While Antique has maintained a cautious stance on Infosys , citing margin pressures and limited changes in organic growth guidance, Nuvama remains optimistic about Dr. Reddy's Laboratories, driven by pipeline progress and a strong outlook for its CDMO business. Explore courses from Top Institutes in Please select course: Select a Course Category Healthcare Degree Cybersecurity CXO Digital Marketing PGDM MBA Public Policy MCA Data Science Design Thinking Leadership others Data Analytics Others Operations Management Artificial Intelligence Project Management Product Management Data Science healthcare Technology Finance Management Skills you'll gain: Financial Analysis in Healthcare Financial Management & Investing Strategic Management in Healthcare Process Design & Analysis Duration: 12 Weeks Indian School of Business Certificate Program in Healthcare Management Starts on Jun 13, 2024 Get Details Meanwhile, Motilal Oswal has reiterated its bullish view on Tata Consumer Products , expecting margin expansion and synergies from recent acquisitions to support earnings growth. Here's a summary of their recommendations and insights for the next 12 months. We have compiled key brokerage recommendations from ET Now and other sources: Antique on Infosys: Hold | Target price: Rs 1,750 Antique has maintained a 'Hold' rating on Infosys with a target price of Rs 1,750. While the company delivered a strong quarterly performance, its organic growth guidance remains largely unchanged. Infosys reported a robust total contract value (TCV) of $3.8 billion, reflecting solid deal bookings. However, discretionary spending remains weak, and the company continues to face margin headwinds. As a result, EPS estimates for FY26 and FY27 remain unchanged. Nuvama on Dr. Reddy's Laboratories: Buy | Target: Rs 1,486 | LTP: Rs 1,247 | Upside: 19% Nuvama has maintained a 'Buy' rating on Dr. Reddy's Laboratories with a target price of Rs 1,486, implying a 19% upside from the last traded price of Rs 1,247. Though the company's Q1 performance was below expectations, new growth drivers are emerging. Semaglutide's progress in Canada remains on track, and a US filing for Abatacept is expected—both positive developments. The CDMO business is expected to contribute $100 million in FY26, with a target of reaching $300 million by FY30—a significant upside surprise. Additionally, the company has reaffirmed its 25% margin guidance, backed by ongoing cost optimisation efforts. Motilal Oswal on Tata Consumer Products: Buy | Target: Rs 1,270 (earlier Rs 1,300) | LTP: Rs 1,062 | Upside: 19% Motilal Oswal has reiterated its 'Buy' rating on Tata Consumer Products, revising the target price slightly to Rs 1,270 from Rs 1,300, indicating a 19% upside from the current price of Rs 1,062. The brokerage expects moderating tea prices to support margin expansion starting Q2FY26. Consolidated margins are likely to improve, led by the tea business, while the international segment is expected to sustain its growth. Synergies from the integration of Capital Foods and Organic India are also expected to boost the domestic food segment. The company has guided for ~16% EBITDA margin by Q3FY26. Motilal has accordingly raised its EBITDA estimates for FY26 and FY27 by 7% and 3%, respectively. ( Disclaimer : Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of The Economic Times)
Business Upturn
12 hours ago
- Business
- Business Upturn
Dr Reddy's stock: CLSA, Jefferies recommend sell, Morgan Stanley says hold — here's why
By Arunika Jain Published on July 24, 2025, 08:40 IST Top brokerages have delivered a mixed outlook on Dr. Reddy's Laboratories following its Q1FY26 results. While Jefferies and CLSA retained their Underperform ratings citing concerns over U.S. business momentum and gRevlimid tapering, Morgan Stanley maintained an Equal-Weight stance with a ₹1,298 target. CLSA: Cautious on U.S. growth taper CLSA kept an Underperform rating with a target of ₹1,120, saying Q1 earnings were in line with estimates. However, it expects the U.S. base business to be flat or grow at low single digits, and noted that gRevlimid sales could start tapering from Q3FY26. The potential launch of Semaglutide in Canada and India may partly offset this slowdown, CLSA added. Jefferies: Q1 miss, watching key launches Jefferies also retained an Underperform rating with a lower target of ₹1,100, citing a Q1 miss due to a decline in U.S. sales, particularly gRevlimid and the base business. SG&A and R&D expenses stayed elevated. However, Jefferies is watching two key pipeline catalysts: the approval of gOzempic in Canada and U.S. filing for Abatacept, which it believes could meaningfully contribute to revenue if launched on time. Morgan Stanley: Balanced view Morgan Stanley took a more neutral stance with an Equal-Weight rating and a target price of ₹1,298. It noted that Q1 revenue grew 11% YoY, but gross margins declined due to higher price erosion and lower operating leverage. EBITDA was in line, while PAT rose 2% YoY. Morgan Stanley believes the risk-reward remains balanced. Disclaimer: The brokerage views expressed above are solely those of the respective firms. This article does not constitute investment advice. Readers are advised to consult their financial advisor before making any investment decisions. Ahmedabad Plane Crash Arunika Jain, a graduate in Mass Communication, brings a fresh perspective to the world of journalism. Arunika has a passion for writing finance and corporate news at You can write to her at [email protected]
Business Upturn
12 hours ago
- Business
- Business Upturn
Dr Reddy's share: Jefferies sees 12% downside after Q1 miss, cuts target to Rs 1,100
By News Desk Published on July 24, 2025, 08:35 IST Jefferies has maintained its Underperform rating on Dr. Reddy's Laboratories, lowering expectations with a target price of ₹1,100 per share. This implies a 12% downside from the current market price of ₹1,248.00. The brokerage flagged that Q1FY26 earnings missed estimates, primarily due to lower US sales, which were impacted by a sequential decline in both the gRevlimid contribution and the base business. In contrast, performance in other markets was largely in line with expectations. Jefferies also noted that SG&A expenses and R&D investments remained elevated during the quarter, weighing on profitability. Looking ahead, the brokerage is closely watching two pipeline triggers: Approval of gOzempic in Canada U.S. filing for Abatacept Jefferies has built in a timely launch and meaningful sales contribution from both products into its base case but remains cautious due to the near-term headwinds. Disclaimer: The brokerage views expressed above are those of Jefferies. This article does not constitute investment advice. Readers are advised to consult their financial advisor before making any investment decisions. Ahmedabad Plane Crash News desk at
Medscape
03-07-2025
- Health
- Medscape
Abatacept Beats HCQ in Halting RA in Palindromic Rheumatism
TOPLINE: Abatacept outperformed hydroxychloroquine (HCQ) in preventing patients with palindromic rheumatism (PR) from progressing to rheumatoid arthritis (RA). METHODOLOGY: Researchers randomly assigned 70 individuals with PR who were seropositive for rheumatoid factor or anti-citrullinated protein antibodies in a 1:1 ratio to receive open-label abatacept (ABA) at 125 mg/week or HCQ at 5 mg/kg/day for 1 year. All patients had symptom durations of over 3 months but under 3 years and were not taking any disease-modifying antirheumatic drugs or glucocorticoids. Patients were followed for an additional year to track RA development. TAKEAWAY: At month 24, three patients (8.8%) in the ABA group progressed to RA compared with 10 patients (27.8%) in the HCQ group (P = .047). Patients treated with HCQ who developed RA generally progressed in the first 12 months of the trial, whereas patients treated with ABA who developed RA did so at the end of the second year. The ABA group also had higher persistent remission rates of PR than the HCQ group (55.9% vs 22.9%). Serious adverse events were uncommon in both treatment groups. IN PRACTICE: 'In patients with recent-onset seropositive palindromic rheumatism, abatacept significantly decreased the rate of RA progression in comparison with hydroxychloroquine at 2 years follow-up,' said study author Raimon Sanmarti, MD, PhD, of the Hospital Clínic de Barcelona, Barcelona, Spain. 'Abatacept is also more efficacious than hydroxychloroquine in the control of symptoms of seropositive palindromic rheumatism.' SOURCE: Sanmarti presented the study in an oral abstract session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. LIMITATIONS: This was an open-label study with a relatively small sample of patients. Over the 2-year trial, eight patients in the HCQ group and five patients in the ABA group exited the trial or were lost to follow-up. DISCLOSURES: The Fundació Clínic per a la Recerca Biomèdica sponsored the study. Sanmarti disclosed financial relationships with Bristol Myers Squibb, AbbVie, MSD, Roche, UCB, Pfizer, Eli Lilly, Gebro, Janssen, Sanofi, Gilead, and Adacyte.
